Dia sells SUPN 14.15: We will continue to build our patent estate to provide our products with the protection they are entitled to.

Supernus Announces Issuance of Fifth U.S. Supernus has several additional patent applications for extended-release oxcarbazepine and extended-release topiramate pending in other geographic regions. I was out of a few around cost, booked a few decent gains but I did take a couple very small losses. I sold out of almost everything pretty early in the day into the little rip that we see so many times after a large gap down open. SUPN has been the topic of several analyst reports.


Rosenda:
About Supernus Pharmaceuticals, Inc.

Brandy:
In other Supernus Pharmaceuticals news, CFO Gregory S.

Raye:
The company had revenue of $35.10 million for the quarter, compared to analyst estimates of $34.07 million.

Tamesha:
The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

Jonna:
These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Daphine:
Please refer to the information below for conference call dial-in information and webcast registration.

An:
ET, on Wednesday, August 5, 2015. An accompanying webcast also will be provided.

Tarra:
This compares to prior guidance of net product sales of $130 million to $140 million and operating income of $6 million to $10 million.

Eileen:
The Company expects that net product sales will range from $135 million to $140 million, with operating income ranging from $8 million to $10 million.

Georgianne:
Diluted earnings per share were $0.03 in the second quarter ended June 30, 2015, compared to $0.08 in the same period last year.

Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)
//stockhand.net/us/?q=nasdaq%3Asupn&id=362922